Clinical characteristic of thoracic malignancy patients with coronavirus disease 2019 related to mitigation strategy in dharmais national cancer center hospital, Indonesia

Hanafi, A.; Soetandyo, N.; Jayusman, A. M.; Widjaja, L.; Dwijayanti, F.; Imelda, P.

AIM: This study aims to describe the clinical data and disease severity of thoracic malignancy patients with coronavirus disease 2019 (COVID-19) and its relation to the mitigation process at the Dharmais National Cancer Center, Indonesia. METHODS: A total of 5256 cancer patients registered from May 2020 to March 2021. There were 681 cancer patients diagnosed with COVID-19. Forty-five thoracic malignancy patients were enrolled. Data from medical records were obtained at the Dharmais Cancer Hospital, then analyzed using SPSS version 25. Comparative result was considered significant, as p < 0.05. RESULTS: There were 12.9% of total patients registered infected by COVID-19, which 6% with thoracic malignancy dominated by non-small cell lung carcinoma (57.8%). Patients who have asymptomatic (31.1%), mild (13.3%), and moderate COVID-19 disease (8.9%) were alive. Patient with severe disease (46.7%) tends to deteriorate. Neutrophilia (mean 78.0%), lymphopenia (mean 13.0%), high neutrophil-to-lymphocyte ratio (mean 13.1), hyperuricemia (mean 31.6 mg/dL), high fibrinogen (mean 521.7 mg/dL), and high d-dimer (mean 3821.6 ng/mL) were significantly associated with disease severity (p < 0.05). CONCLUSION: Only small number of cancer patients affected by COVID-19 and mostly does not progress to severe disease, showing that the strict mitigation strategy was successful. Severe disease patients have a poor prognosis, with neutrophilia, lymphopenia, high neutrophil-to-lymphocyte ratio, hyperuricemia, high fibrinogen, and high d-dimer may be valuable for predicting poor prognosis.